Ken Herrmann
#143,070
Most Influential Person Now
Researcher
Ken Herrmann's AcademicInfluence.com Rankings
Ken Herrmannengineering Degrees
Engineering
#5449
World Rank
#6708
Historical Rank
Electrical Engineering
#1516
World Rank
#1610
Historical Rank
Ken Herrmanncomputer-science Degrees
Computer Science
#6993
World Rank
#7364
Historical Rank
Machine Learning
#2442
World Rank
#2474
Historical Rank
Artificial Intelligence
#2727
World Rank
#2770
Historical Rank
Database
#4057
World Rank
#4219
Historical Rank
Download Badge
Engineering Computer Science
Ken Herrmann's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Ken Herrmann Influential?
(Suggest an Edit or Addition)Ken Herrmann's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. (2007) (774)
- 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 (2017) (480)
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (2021) (478)
- Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. (2006) (459)
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. (2019) (394)
- The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer (2007) (351)
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT (2017) (310)
- 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning (2017) (203)
- PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data (2015) (200)
- EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) (2019) (196)
- Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors (2018) (189)
- 2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy (2005) (187)
- 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT (2016) (173)
- 18F-FDG PET–Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial (2011) (172)
- In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma (2015) (170)
- First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT (2010) (165)
- Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma (2007) (164)
- SPECT-CT (2008) (164)
- Comparison of Integrin αvβ3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG (2007) (163)
- First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease (2016) (161)
- PSMA Ligands for PET Imaging of Prostate Cancer (2017) (156)
- Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging (2015) (155)
- Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches (2010) (153)
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy (2017) (153)
- 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients (2016) (148)
- Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study (2008) (140)
- The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis (2017) (139)
- Textural Parameters of Tumor Heterogeneity in 18F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer (2014) (135)
- Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer (2019) (134)
- Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy (2015) (132)
- Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions (2017) (127)
- Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis (2007) (126)
- 177Lu-PSMA Radioligand Therapy for Prostate Cancer (2017) (123)
- 68 Ga-PSMA PET / CT : Joint EANM and SNMMI procedure guideline for prostate cancer imaging : version 1 . 0 (2017) (123)
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET (2021) (122)
- The Sensitivity of [11C]Choline PET/CT to Localize Prostate Cancer Depends on the Tumor Configuration (2011) (114)
- Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence (2017) (113)
- 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study (2017) (113)
- [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values (2017) (111)
- EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. (2019) (108)
- Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction (2007) (107)
- CXCR4 Ligands: The Next Big Hit? (2017) (107)
- Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. (2018) (102)
- Ga-PSMA PET / CT : Joint EANM and SNMMI procedure guideline for prostate cancer imaging : version 1 . 0 (2017) (101)
- Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe 68Ga-Pentixafor (2015) (101)
- Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review (2014) (100)
- EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma (2015) (94)
- Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. (2018) (93)
- Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial (2014) (93)
- 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib (2011) (90)
- [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience (2016) (87)
- Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. (2013) (86)
- The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT (2009) (86)
- Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy (2016) (84)
- Comparison of the Amino Acid Tracers 18F-FET and 18F-DOPA in High-Grade Glioma Patients (2014) (83)
- Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer (2020) (82)
- COVID-19 pandemic: guidance for nuclear medicine departments (2020) (82)
- The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches (2019) (82)
- Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. (2012) (81)
- Radiotheranostics: a roadmap for future development. (2020) (79)
- CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma (2017) (78)
- 68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma (2016) (78)
- Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer (2018) (75)
- 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy (2012) (75)
- 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement (2016) (74)
- Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment (2011) (72)
- Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. (2021) (71)
- Consensus on molecular imaging and theranostics in prostate cancer. (2018) (70)
- 18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer (2009) (70)
- Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response (2008) (69)
- PET/CT in Oncology: Current Status and Perspectives (2013) (69)
- Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. (2021) (69)
- Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies (2017) (69)
- Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine (2008) (68)
- COVID-19-Related Fear and Health-Related Safety Behavior in Oncological Patients (2020) (68)
- Cost-Effectiveness of Hybrid PET/CT for Staging of Non–Small Cell Lung Cancer (2010) (66)
- Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective (2015) (65)
- Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach (2017) (64)
- [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity (2016) (62)
- 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs (2014) (61)
- Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer (2011) (60)
- Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences (2020) (60)
- Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting (2019) (60)
- Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy (2020) (59)
- The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies (2008) (58)
- [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. (2008) (57)
- (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go. (2011) (56)
- Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker 18F-Fluorothymidine (2009) (56)
- PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis (2020) (56)
- Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. (2009) (54)
- Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial (2020) (54)
- Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. (2021) (53)
- Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence (2017) (53)
- Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches (2010) (52)
- Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients (2017) (51)
- Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma (2018) (50)
- Comparison of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours (2012) (50)
- Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients (2019) (49)
- 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. (2014) (49)
- Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT (2017) (49)
- Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging (2014) (49)
- EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) (49)
- [(68)Ga]Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction. (2015) (49)
- Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020 (2020) (48)
- 11C–MET PET/MRI for detection of recurrent glioma (2018) (48)
- 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions (2017) (48)
- Value of functional imaging by PET in esophageal cancer. (2015) (48)
- Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. (2021) (47)
- Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer (2018) (47)
- PSMA ligands in prostate cancer - Probe optimization and theranostic applications. (2017) (46)
- Phenotyping of Tumor Biology in Patients by Multimodality Multiparametric Imaging: Relationship of Microcirculation, αvβ3 Expression, and Glucose Metabolism (2010) (46)
- Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients (2014) (46)
- MET Expression in Advanced Non–Small‐Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy (2018) (46)
- Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients (2021) (45)
- Semiautomatically Quantified Tumor Volume Using 68Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer (2020) (45)
- The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. (2008) (44)
- Intraoperative 3-D imaging improves sentinel lymph node biopsy in oral cancer (2014) (44)
- Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria (2019) (43)
- Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand (2016) (43)
- PET/MRI Versus PET/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations (2019) (43)
- The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. (2020) (41)
- Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. (2015) (41)
- FDG-PET imaging in hematological malignancies. (2016) (41)
- 18F‐Fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma (2013) (41)
- [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner (2012) (41)
- Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). (2021) (40)
- Assessment of 68 Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer A Prospective Single-Arm Clinical Trial (2019) (40)
- In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors (2008) (38)
- Evaluation of the Genisys4, a Bench-Top Preclinical PET Scanner (2013) (38)
- Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT (2015) (38)
- Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors (2019) (38)
- Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment (2008) (37)
- Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy (2016) (36)
- FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. (2012) (36)
- Integrated 18F–FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial (2017) (35)
- Comparison of 18F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix (2017) (35)
- Therapy assessment in prostate cancer using choline and PSMA PET/CT (2017) (34)
- [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer (2018) (34)
- Evaluation of Prostate Cancer with 11C-Acetate PET/CT (2016) (34)
- Freehand SPECT‐guided sentinel lymph node biopsy in early oral squamous cell carcinoma (2014) (33)
- Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel Analysis (2015) (32)
- Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer (2016) (32)
- A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma (2011) (32)
- Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer (2018) (32)
- EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy (2020) (32)
- 18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine (2017) (32)
- Clinical Value and Limitations of [11C]-Methionine PET for Detection and Localization of Suspected Parathyroid Adenomas (2009) (32)
- Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference (2019) (32)
- Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview (2017) (31)
- Monitoring response to therapeutic interventions in patients with cancer. (2009) (31)
- 3D scintigraphic imaging and navigation in radioguided surgery: freehand SPECT technology and its clinical applications (2016) (31)
- Whitening and Impaired Glucose Utilization of Brown Adipose Tissue in a Rat Model of Type 2 Diabetes Mellitus (2017) (31)
- Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. (2020) (31)
- Radiotheranostics in oncology: current challenges and emerging opportunities (2022) (30)
- The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients (2016) (30)
- Comparison of 18F–FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study (2018) (29)
- Tumor-Associated Macrophages in Glioblastoma Multiforme—A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy? (2015) (29)
- Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT (2017) (29)
- Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites (2016) (29)
- Comparison of Different SUV-Based Methods for Response Prediction to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer by FDG-PET and MRI (2008) (28)
- Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes (2016) (28)
- Impact of COVID-19 on Nuclear Medicine in Germany, Austria and Switzerland: An International Survey in April 2020 (2020) (28)
- 11 C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma (2015) (27)
- 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients (2017) (27)
- Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL (2014) (27)
- Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. (2020) (27)
- Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis (2013) (26)
- Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer (2017) (26)
- [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model (2008) (26)
- Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient (2020) (26)
- PET Response Criteria in Solid Tumors Predicts Progression-Free Survival and Time to Local or Distant Progression After Chemotherapy with Regional Hyperthermia for Soft-Tissue Sarcoma (2015) (26)
- Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented (2017) (25)
- Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging (2018) (25)
- Radionuclide Imaging of Neurohormonal System of the Heart (2015) (25)
- Nuclear medicine services after COVID-19: gearing up back to normality (2020) (25)
- Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization (2019) (25)
- Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial (2021) (24)
- 18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis (2020) (24)
- Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. (2019) (24)
- Lu-PSMA Radioligand Therapy for Prostate Cancer (2017) (24)
- Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort (2021) (24)
- False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial (2020) (24)
- In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CT. (2020) (23)
- Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: Preliminary results. (2018) (23)
- EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (2019) (23)
- Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. (2018) (23)
- Initial Preclinical Evaluation of 18F-Fluorodeoxysorbitol PET as a Novel Functional Renal Imaging Agent (2016) (23)
- Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma (2019) (22)
- Nuclear medicine and molecular imaging advances in the 21st century. (2020) (22)
- Hybrid total-body pet scanners—current status and future perspectives (2021) (22)
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study (2022) (21)
- Sentinel lymph node biopsy in oral and oropharyngeal squamous cell carcinoma: current status and unresolved challenges (2015) (21)
- Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality? (2021) (21)
- Intraoperative 68Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study (2020) (21)
- Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer (2021) (21)
- Performance of cone beam computed tomography in comparison to conventional imaging techniques for the detection of bone invasion in oral cancer. (2015) (21)
- 11C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma (2015) (21)
- The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. (2021) (21)
- Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI (2018) (20)
- Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. (2020) (20)
- CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor. (2018) (20)
- Joint Imaging Platform for Federated Clinical Data Analytics (2020) (20)
- Theranostics in Boron Neutron Capture Therapy (2021) (20)
- Dual‐phase hybrid 18F‐Fluoride Positron emission tomography/MRI in ankylosing spondylitis: Investigating the link between MRI bone changes, regional hyperaemia and increased osteoblastic activity (2018) (20)
- Novel Structured Reporting Systems for Theranostic Radiotracers (2019) (20)
- Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer (2018) (20)
- Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding (2021) (19)
- Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI (2017) (19)
- Comparison of the clinical performance of upper abdominal PET/DCE-MRI with and without concurrent respiratory motion correction (MoCo) (2018) (19)
- Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence (2015) (19)
- Potential Impact of 68 Ga-PSMA-11 PET / CT on the Planning of Definitive Radiation Therapy for Prostate Cancer (2018) (19)
- Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients (2021) (19)
- Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment (2015) (19)
- 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma (2021) (19)
- Imaging Inflammation with Positron Emission Tomography (2021) (19)
- Diagnosis and Screening of Patients with Fabry Disease (2020) (19)
- Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET (2019) (18)
- [18F]FDG PET/MR enterography for the assessment of inflammatory activity in Crohn’s disease: comparison of different MRI and PET parameters (2018) (18)
- Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers (2009) (18)
- Assessment of Ileocolonic Inflammation in Crohn’s Disease: Which Surrogate Marker Is Better—MaRIA, Clermont, or PET/MR Index? Initial Results of a Feasibility Trial (2018) (18)
- Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer (2021) (18)
- In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts (2019) (18)
- 68Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. (2019) (18)
- Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease (2014) (18)
- PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study (2020) (18)
- Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients (2020) (17)
- Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer (2014) (17)
- PET/CT for staging lung cancer: costly or cost-saving? (2011) (16)
- Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review (2021) (16)
- Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation (2019) (16)
- Cholinergic activity and levodopa‐induced dyskinesia: a multitracer molecular imaging study (2017) (16)
- Association of the VEGF 936C>T Polymorphism with FDG Uptake, Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the Esophagogastric Junction (2011) (16)
- Mental Health Burden of German Cancer Patients before and after the Outbreak of COVID-19: Predictors of Mental Health Impairment (2021) (16)
- Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation (2019) (16)
- Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? (2019) (15)
- Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway (2017) (15)
- Current and Emerging Applications (2018) (15)
- Localization of Parathyroid Adenoma With Real-Time Ultrasound: Freehand SPECT Fusion. (2016) (15)
- Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience (2018) (14)
- iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer? (2015) (14)
- Sympathetic nerve damage and restoration after ischemia-reperfusion injury as assessed by 11C-hydroxyephedrine (2016) (14)
- Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. (2015) (14)
- The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy (2016) (14)
- Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. (2021) (14)
- 68Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions? (2016) (14)
- Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation (2019) (14)
- Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation (2019) (14)
- 18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas (2019) (14)
- Three-Phase Bone Scintigraphy for Imaging Osteoradionecrosis of the Jaw (2014) (14)
- Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. (2014) (14)
- Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma (2014) (14)
- Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? (2017) (14)
- Impact of 68 Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial (2020) (13)
- 18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed? (2017) (13)
- Changing trends of incidence and prognosis of thyroid carcinoma (2019) (13)
- PET and PET-CT in esophageal and gastric cancer. (2011) (13)
- Targeting CXCR 4 ( CXC Chemokine Receptor Type 4 ) for Molecular Imaging of Aldosterone-Producing Adenoma (13)
- Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria (2022) (13)
- Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma (2017) (13)
- Multi-technique hybrid imaging in PET/CT and PET/MR: what does the future hold? (2016) (13)
- 18F-flutemetamol positron emission tomography in cardiac amyloidosis (2020) (13)
- Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era (2020) (13)
- Activation of brown adipose tissue in hypothyroidism (2015) (13)
- Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre (2022) (13)
- Characterization of Site-Specifically Conjugated Monomethyl Auristatin E– and Duocarmycin-Based Anti-PSMA Antibody–Drug Conjugates for Treatment of PSMA-Expressing Tumors (2017) (12)
- Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma (2019) (12)
- Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer. (2021) (12)
- Perceived Misinterpretation Rates in Oncologic 18F-FDG PET/CT Studies: A Survey of Referring Physicians (2014) (12)
- Neuroendocrine Tumors of the Gastrointestinal Tract (2017) (12)
- Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer (2021) (12)
- Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis (2020) (12)
- PET Tracers in Musculoskeletal Disease beyond FDG (2014) (12)
- Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0 (2022) (11)
- The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. (2019) (11)
- Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus (2019) (11)
- Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study (2017) (11)
- A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study (2022) (11)
- Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision (2020) (11)
- Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma (2021) (11)
- Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. (2013) (11)
- Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls. (2014) (11)
- Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: a meta-analysis (2021) (10)
- First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using 68Ga-PSMA-11 (2020) (10)
- Radiomics Analysis of Multiparametric PET/MRI for N- and M-Staging in Patients with Primary Cervical Cancer (2020) (10)
- Three-dimensional magnetic resonance imaging using single breath-hold k-t BLAST for assessment of global left ventricular functional parameters. (2013) (10)
- Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer. (2020) (10)
- [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein]. (2018) (10)
- FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials (2021) (10)
- RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer. (2019) (10)
- Cardiac PET/MRI: Current Clinical Status and Future Perspectives. (2020) (10)
- 2-[F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy (2005) (10)
- Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithms. (2020) (10)
- Primary central nervous system lymphoma and meningioma in DOTATATE PET/CT. (2013) (10)
- Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy (2014) (9)
- NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization (2019) (9)
- SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors: A Comprehensive Multidisciplinary Team Approach (2015) (9)
- Recommended administered activities for 68Ga-labelled peptides in paediatric nuclear medicine (2016) (9)
- [Imaging procedures for gastrointestinal stromal tumors]. (2009) (9)
- Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer (2021) (9)
- Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial (2019) (9)
- Chaperone Therapy in Fabry Disease (2022) (9)
- Lutetium-177-PSMA-Radioligandentherapie (2018) (9)
- An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine (2022) (9)
- Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities (2022) (9)
- Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study. (2022) (9)
- 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial (2019) (9)
- From NETTER to PETTER: PSMA-Targeted Radioligand Therapy (2017) (8)
- Changes in the global impact of COVID-19 on nuclear medicine departments during 2020: an international follow-up survey (2021) (8)
- PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease (2021) (8)
- [Morphologic diagnostic criteria of noninvasive follicular neoplasia with papillary-like nuclear features (NIFTP) : A diagnostic challenge for the patient's benefit]. (2019) (8)
- [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors (2021) (8)
- Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography (2021) (8)
- Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial. (2018) (8)
- Evaluation of 18F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion (2020) (8)
- 18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation (2014) (8)
- Diagnostic Performance of Kwak, EU, ACR, and Korean TIRADS as Well as ATA Guidelines for the Ultrasound Risk Stratification of Non-Autonomously Functioning Thyroid Nodules in a Region with Long History of Iodine Deficiency: A German Multicenter Trial (2021) (8)
- Quantitative performance of 124I PET/MR of neck lesions in thyroid cancer patients using 124I PET/CT as reference (2018) (8)
- Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision (2020) (7)
- Quantitative performance evaluation of 124I PET/MRI lesion dosimetry in differentiated thyroid cancer (2017) (7)
- 18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer (2015) (7)
- Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study (2022) (7)
- Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography (2016) (7)
- 18F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET? (2020) (7)
- Tumor localization in ectopic Cushing syndrome using combined PET/CT imaging. (2013) (7)
- Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma (2020) (7)
- The Potential of PET/MRI Imaging in Oncology: a Comment to a Summary Report of the First PET/MRI Workshop in Tuebingen in 2012 (2013) (7)
- Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC (2021) (7)
- PET imaging in prostate cancer, future trends: PSMA ligands (2016) (7)
- Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns? (2020) (7)
- Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial (2019) (7)
- PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study. (2020) (7)
- Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol (2021) (7)
- FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. (2021) (7)
- Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography (2021) (7)
- Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy (2014) (7)
- Molecular Imaging for Primary Staging of Prostate Cancer. (2019) (6)
- Immunohistochemical Profile and 47-Gene Next-Generation Sequencing (NGS) Solid Tumor Panel Analysis of a Series of 13 Strumal Carcinoids (2020) (6)
- Repeatability of 68Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume (2021) (6)
- Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including 18F-FDG PET/MRI, in Newly Diagnosed Breast Cancer: A Comparative Study Using Histopathology as the Reference Standard (2021) (6)
- Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET (2007) (6)
- Inversion-recovery single-shot cardiac MRI for the assessment of myocardial infarction at 1.5 T with a dedicated cardiac coil. (2012) (6)
- [Diagnosis and multimodal therapy for hepatocellular carcinoma]. (2010) (6)
- Clinical Use of PET/MR in Oncology: An Update. (2021) (6)
- EJNMMI supplement: bringing AI and radiomics to nuclear medicine (2019) (6)
- Peptide Receptor Radionuclide Therapy for Sarcoidosis. (2016) (6)
- Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer (2022) (6)
- Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [18F]FDG PET/CT and [18F]FDG PET/MRI (2020) (6)
- Driving the Future of Nuclear Medicine (2019) (6)
- Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312) (2021) (6)
- Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment (2020) (6)
- PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study. (2011) (6)
- Evaluation of the Predictive Potential of 18F-FDG PET and DWI Data Sets for Relevant Prognostic Parameters of Primary Soft-Tissue Sarcomas (2021) (6)
- PET/MR Imaging of the Female Pelvis. (2019) (6)
- Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine. (2022) (5)
- Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a Phantom study. (2021) (5)
- Comprar Radioguided Surgery. Current Applications And Innovative Directions In Clinical Practice | Ken Herrmann | 9783319260495 | Springer (2016) (5)
- Early ResponseAssessment Using 3 ¶-Deoxy-3 ¶-[ 18 F ] Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin ’ s Lymphoma (2007) (5)
- Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe (2020) (5)
- Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases (2018) (5)
- Hybrid imaging of the abdomen and pelvis (2020) (5)
- Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases (2020) (5)
- PET for Initial and Early Response Imaging in Mantle Cell Lymphoma (2011) (5)
- Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. (2020) (5)
- Evaluation of improved attenuation correction in whole-body PET/MR on patients with bone metastasis using various radiotracers (2020) (5)
- Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis (2022) (5)
- Comparison of 18F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis. (2020) (5)
- Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. (2021) (5)
- Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? (2017) (4)
- [PSMA radioligand therapy in patients with advanced prostate cancer]. (2020) (4)
- Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy (2021) (4)
- Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours (2017) (4)
- Nuclear medicine theranostics comes of age. (2021) (4)
- Virtual Biopsy: Just an AI Software or a Medical Procedure? (2022) (4)
- Assessing Response to Therapy in Esophageal (2009) (4)
- Diagnostic Performance of Simultaneous [18F]-FDG PET/MR for Assessing Endoscopically Active Inflammation in Patients with Ulcerative Colitis: A Prospective Study (2020) (4)
- Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results (2021) (4)
- Nuclear Medicine Beyond VISION (2021) (4)
- Comparison of acceptance of PET/MR enterography and ileocolonoscopy in patients with inflammatory bowel diseases. (2020) (4)
- Reply: Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way (2018) (4)
- Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted? (2014) (4)
- PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study (2021) (4)
- Direct proton range verification using oxygen-18 enriched water as a contrast agent (2021) (4)
- Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC (2021) (4)
- Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities (2018) (4)
- Early Results of Intraoperative68Ga-PSMA Cerenkov Luminescence Imaging in Radical Prostatectomy (2019) (4)
- Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy (2021) (4)
- Differentiation of an unclear splenic lesion in a patient with cholangiocarcinoma. (2014) (4)
- [Importance of PET in surgery of esophageal cancer]. (2014) (4)
- EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. (2022) (4)
- Diagnostic accuracy of 18 F – FDG PET / CT and MR imaging in patients with adenoid cystic carcinoma (2018) (4)
- Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging (2019) (4)
- 576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (2021) (4)
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 (2023) (3)
- 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography May Exclude Malignancy in Sonographically Suspicious and Scintigraphically Hypofunctional Thyroid Nodules and Reduce Unnecessary Thyroid Surgeries. (2017) (3)
- 18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair (2014) (3)
- Pancreatic and hepatobiliary cancers. (2011) (3)
- Chapter 6 – Colorectal Cancer (2018) (3)
- Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer (2022) (3)
- Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid 68Ga-DOTATOC PET/MRI. (2021) (3)
- “COVID-19 Pandemic as stimulator to Re-Establish Nuclear Medicine as Clinical Specialty” based on a report of Prof. Dr. Ignasi Carrio (2020) (3)
- Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience (2021) (3)
- A Role of PET/MR in Breast Cancer? (2022) (3)
- Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition (2021) (3)
- Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (2020) (3)
- Molecular Imaging and Therapy of Colorectal and Anal Cancer. (2020) (3)
- Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial. (2020) (3)
- European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees (2022) (3)
- Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy (2021) (3)
- Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence. (2020) (3)
- Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy (2020) (3)
- Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. (2019) (3)
- Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study (2021) (3)
- Primary bone marrow diffuse large B‐cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms (2014) (3)
- Correction to: Nuclear medicine services after COVID-19: gearing up back to normality (2020) (3)
- Head-to-head comparison of 68 Ga-PSMA-11 PET/CT and 18 F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence (2017) (3)
- Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center (2022) (3)
- A Conversation Between Susanne Schaffert and Ken Herrmann (2019) (3)
- A Role for PET/CT in response assessment of malignant pleural mesothelioma. (2022) (3)
- Imaging inflammation after myocardial infarction. Implications for prognosis and therapeutic guidance. (2020) (3)
- Impact of prompt gamma coincidence correction on absorbed dose estimation in differentiated thyroid cancer using 124I PET/CT imaging (2018) (3)
- [PSA increase after definitive treatment]. (2019) (3)
- Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities (2022) (3)
- Chapter 4 – [18F]‐Labeled PET and PET/CT Compounds in Oncology (2008) (3)
- Insights into immunometabolism: A dataset correlating the 18FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancer (2021) (2)
- A novel theranostic concept for Adrenocortical Neoplasia targeting the chemokine receptor CXCR4 (2015) (2)
- Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging—utilization of a short-pass filter to reduce technical pitfalls (2021) (2)
- Alternative PET Tracers in Musculoskeletal Disease. (2010) (2)
- Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using ( 18 F)Fluorothymidine-PET (2015) (2)
- Clinical applications of PET/CT and SPECT/CT imaging (2017) (2)
- [68Ga]Pentixafor: A Novel PET Tracer for Imaging CXCR4 Status in Patients with Multiple Myeloma (2014) (2)
- [18F-FDG-PET in therapy response of esophageal cancer]. (2007) (2)
- N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard (2021) (2)
- Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma (2021) (2)
- Evaluation of feasibility of freehand SPECT in the operating room (2010) (2)
- [Impact of COVID-19 on Nuclear Medicine Procedures in Germany 2020 - Results of a National Survey]. (2021) (2)
- Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. (2020) (2)
- An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases (2021) (2)
- Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study. (2021) (2)
- Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. (2020) (2)
- 18F-florbetaben positron emission tomography detects cardiac involvement in systemic AA amyloidosis (2020) (2)
- Small-Animal PET Imaging of Isolated Perfused Rat Heart (2014) (2)
- Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension (2021) (2)
- The effect of partial volume effect correction on PIB and FDG PET data in MCI and AD patients (2009) (2)
- Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (2021) (2)
- [Rapidly progressive bilateral breast masses]. (2014) (2)
- Production of [11C]Formaldehyde by the XeF2 mediated oxidation of [11C]Methanol and its application in the labeling of α-(N-[11C]Methylamino)isobutyric acid. (2019) (2)
- [Feasibility of flat-panel volumetric computed tomography (fpVCT) in experimental small animal imaging of osteoporosis - initial experience]. (2006) (2)
- European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. (2021) (2)
- Imaging the Inflammatory Response in Checkpoint Inhibition Myocarditis (2021) (2)
- [123/131I](R)-1-[1-(4-iodophenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinylamide (IMAZA) – A novel radiotracer for diagnosis and treatment of adrenocortical tumours – From bench to bedside (2015) (2)
- Corneal confocal microscopy to detect early immune‐mediated small nerve fibre loss in AL amyloidosis (2022) (2)
- Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma (2022) (2)
- Radiation Protection and Occupational Exposure on 68Ga-PSMA-11–Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy (2021) (2)
- Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations (2022) (2)
- First experiences with dynamic renal [68Ga]Ga-DOTA PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate (2022) (2)
- First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma (2022) (2)
- The Future Role of PET Imaging in Metastatic Breast Cancer (2021) (2)
- 18F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma (2021) (1)
- PSA-Anstieg nach definitiver Therapie (2019) (1)
- Oncologic PET/CT interpretation and reporting approaches (2014) (1)
- A PET for All Seasons: 18F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis? (2017) (1)
- 18 F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer (2018) (1)
- Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers (2022) (1)
- Detection of locally advanced gastric cancer with Fluoro-18-thymidine and Fluoro-18-fluorodeoxyglucose positron emission tomography (2007) (1)
- Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma (2019) (1)
- Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: A sub-study of the VISION trial. (2020) (1)
- Diagnostic findings and treatment in a 51-year-old woman with oncogenic osteomalacia. (2014) (1)
- Comparison of 18 F- FDG PeT- Mr and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis (2020) (1)
- COVID-19 Pandemic: What Have We Learned and What to Expect in the Future? (2021) (1)
- Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET (2022) (1)
- PET/MR Imaging: Current and Emerging Applications (2018) (1)
- Proton Beam Range Verification with Secondary Radiation from Titanium Implants (2019) (1)
- Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial (2020) (1)
- Ga-DOTATATE PET / CT interobserver agreement for neuroendocrine tumor assessments : results from a prospective study on 50 patients (2016) (1)
- Atypical bilateral ventilation/perfusion mismatches in an asymptomatic patient suffering from metastatic thyroid cancer (2021) (1)
- Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT (2022) (1)
- Preclinical and clinical assessment of immune checkpoint inhibitor-associated left ventricular dysfunction (2020) (1)
- Distribution of Functional Status of Thyroid Nodules and Malignancy Rates of Hyperfunctioning and Hypofunctioning Thyroid Nodules in Germany. (2022) (1)
- PET/CT with 18F-FLT Is Unlikely to Cause Significant Hepatorenal or Hematologic Toxicity (2010) (1)
- One Year Later: Global Impact of COVID-19 on Nuclear Medicine Departments; an International Follow-up Survey (2021) (1)
- Evaluation of a new automated assay for high-sensitivity thyroglobulin measurement and comparison with two established high-sensitivity thyroglobulin assays (2021) (1)
- Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
- Fabry Cardiomyopathy: Current Treatment and Future Options (2021) (1)
- Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma (2022) (1)
- Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology (2022) (1)
- Change of tumor cell proliferation during R-CHOP chemotherapy of diffuse large B cell lymphoma (DLBCL) measured by 18FLT-PET (2006) (1)
- Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on 18F-FDG PET/MRI and Machine Learning (2022) (1)
- Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system (2022) (1)
- Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. (2017) (1)
- [ 123/131 I] azetidinylamide a novel radiotracer for diagnosis and treatment of adrenocortical tumours -- from bench to bedside (2015) (1)
- Molecular Imaging of Lymphoma: Future Directions and Perspectives. (2022) (1)
- [Hybrid imaging of the abdomen and pelvis. German version]. (2020) (1)
- [Future Workshop 1.0 - Departure into the future or a flash in the pan?] (2019) (1)
- Comprar PET/MR Imaging. Current and Emerging Applications | Lale Umutlu | 9783319696409 | Springer (2018) (1)
- Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial (2021) (1)
- 68Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: preliminary results from a phase 2/3 prospective trial (2018) (1)
- Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers (2022) (1)
- Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial (2022) (1)
- Metabolic response assessment and PET-guided treatment of esophageal cancer. (2020) (1)
- Metabolic imaging predicts response and prognosis in neoadjuvant treated, locally advanced gastric cancer: Final results of a prospective study (2007) (1)
- 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma (2021) (1)
- Have we overcome choline PET/CT for early detection of prostate cancer recurrence? (2016) (1)
- Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapy. (2015) (1)
- Evidence of a Direct Effect of Myocardial Steatosis on LV Hypertrophy and Diastolic Dysfunction in Adult and Adolescent Obesity (2017) (1)
- 2021: the year [ 177 Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to "A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands" by Dr. Germo Gericke. (2021) (1)
- The disappearance act of Nuclear Medicine in the Netherlands: Just a new trick by the great Harry Houdini? (2021) (1)
- More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer. (2022) (1)
- Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging (2014) (1)
- Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas (2019) (1)
- [68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas (2022) (1)
- LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis (2022) (1)
- Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial (2014) (1)
- Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy (2022) (1)
- Diagnostic effectiveness, cost-effectiveness and prognostic utility of PET/CT in non-small cell lung cancer (NSCLC) (2008) (1)
- Artificial intelligence guided enhancement of digital PET: scans as fast as CT? (2022) (1)
- 2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? (2021) (1)
- The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy (2021) (1)
- Radioguided Surgery of Thyroid Carcinoma Recurrences (2016) (1)
- Effects of Anti–Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective Proof‐of‐Concept Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine (2022) (1)
- Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol (2021) (1)
- Imaging of proliferation in hepatocellular carcinoma (HCC) with the in-vivo marker FLT (2009) (1)
- Comparison of pre- and post-contrast-enhanced attenuation correction using a CAIPI-accelerated T1-weighted Dixon 3D-VIBE sequence in 68Ga-DOTATOC PET/MRI. (2021) (1)
- Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in 18F-FDG PET/MRI (2022) (1)
- Radioguided Sentinel Lymph Node Mapping and Biopsy in Thyroid Cancer (2016) (1)
- Physiologic Uptake, Variants, and Pitfalls (2014) (1)
- Correlation of the apparent diffusion coefficient (ADC) and standardized uptake values (SUV) with overall survival in patients with primary non-small cell lung cancer (NSCLC) using 18F-FDG PET/MRI. (2020) (1)
- EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours—the consensus in a nutshell (2021) (1)
- [Hybrid imaging]. (2020) (1)
- [Fireside chat "§ 13 (2b) AMG in nuclear medicine therapy" - a follow-up event of NuklearMedizin 2020 - Digital]. (2021) (0)
- Practicing Medicine in Wartime Ukraine (2022) (0)
- What Is Theranostics? (2023) (0)
- Image quality and lesion detectability using different simulated activities of 68Ga-PSMA-11 (2019) (0)
- Alternative Tracers in Musculoskeletal (2010) (0)
- Advancing Clinical Trial Innovation in Pancreatic Cancer (2023) (0)
- 68 Ga-PSMA PET/CT Mapping of Early Biochemical Recurrence (PSA <1 ng/mL) After Primary Surgery in 270 Patients: Impact on Salvage Radiation Therapy Planning (2017) (0)
- A European Oncology Leader Looks at PSMA (2022) (0)
- Coefficient of variance of glucose metabolism is a predictive parameter to assess response to neoadjuvant radiochemotherapy of colorectal cancer (2013) (0)
- Clinical impact of 11C-Choline PET/CT in recurrent prostate cancer patients after radical therapy: Which is the real impact on treatment decisions? (2014) (0)
- Correction: Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine. (2022) (0)
- [Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT]. (2023) (0)
- A-B. Scatter plot of the correlations of ADC and 18 F-FDG uptake (B). (2015) (0)
- Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition (2021) (0)
- Correction to: European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees (2022) (0)
- [Oldies (but Goldies): Peritoneal Scintigraphy in Chronic Peritoneal Dialysis Patients]. (2021) (0)
- Oldies (but Goldies): Die Peritonealszintigrafie bei Peritonealdialyse (2021) (0)
- Advancing Nuclear Medicine in Australia over 3 Decades (2022) (0)
- Letter from the Guest Editors (2021) (0)
- SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors (2023) (0)
- Is there a connection between immunohistochemical markers and grading of lung cancer with apparent diffusion coefficient (ADC) and standardised uptake values (SUV) of hybrid 18F‐FDG‐PET/MRI? (2020) (0)
- A Letter from Ukraine (2022) (0)
- Leading in Urology and Pioneering in Social Media Outreach (2022) (0)
- Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis (2022) (0)
- Two weeks of single agent cetuximab (CET) induce a decrease in the tumor glucose-uptake measured by 18FDG-PET during neoadjuvant treatment of locally advanced squamous cell carcinoma (SCC) of the esophagus (2008) (0)
- Fully Automated, High-Dose Radiosynthesis of [18F]PARPi (2022) (0)
- 68Ga-PSMA PET/CT Mapping of Prostate Cancer at Initial Staging: Potential Impact on Definitive Radiation Therapy Planning (2018) (0)
- Towards using secondary gamma-rays from proton-induced radioactivation of titanium implants for off-line field verification (2021) (0)
- Metabolic response-guided treatment individualization in neoadjuvant therapy of locally advanced adenocarcinoma of the esophagogastric junction (AEG) (2007) (0)
- Head-to-head comparison of 68 Ga-PSMA-11 and 18 F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence (2017) (0)
- Interim FDG PET analysis performed by Neural Networks to predict the outcome of patients with aggressive B-cell lymphoma (2021) (0)
- Inversions recovery single shot gradient echo at 1.5T using a dedicated cardiac coil (2010) (0)
- Correction to: Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0 (2022) (0)
- A Conversation Between Ignasi Carrió and Ken Herrmann (2020) (0)
- Publisher Correction to: 18F-florbetaben positron emission tomography detects cardiac involvement in systemic AA amyloidosis (2020) (0)
- Utility of Integrated PET/MRI for the Primary Diagnostic Work-Up of Patients with Ewing Sarcoma: Preliminary Results (2022) (0)
- Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial (2021) (0)
- Effects of anti-TNF-therapy on inflammatory, structural and osteoblastic activity lesions in radiographic axial spondyloarthritis - a prospective proof-of-concept study using PET/MRI of SIJ and spine. (2022) (0)
- Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients? (2022) (0)
- TCRM_A_247814 551..558 (2020) (0)
- Towards a fast PET/MRI protocol for breast cancer imaging: maintaining diagnostic confidence while reducing PET and MRI acquisition times. (2023) (0)
- Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision (2021) (0)
- In-vivo imaging of proliferation in patients with mantle cell lymphoma and correlation with Ki-67 protein expression (2011) (0)
- PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study (2022) (0)
- Early metabolic response evaluation predicts response to neo-adjuvant radio-chemotherapy in patients with advanced rectal cancer (2007) (0)
- Single agent cetuximab induces a decrease in the tumor glucose-uptake measured by 18F-fluorodeoxyglucose positron emission tomography in advanced squamous cell carcinoma of the esophagus (2008) (0)
- Personalized Treatment for Patients With Lung Cancer. (2023) (0)
- Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. (2022) (0)
- Radionuclide Imaging of Neurohormonal System of the (2015) (0)
- Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response. (2023) (0)
- Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma (2017) (0)
- Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide Therapy (2022) (0)
- Irène Buvat and Ken Herrmann Talk with Alexander Stremitzer, Kevin Tobia, and Aileen Nielsen (2020) (0)
- 18 F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma (2022) (0)
- The potential influence of [11C]-Choline PET/CT on the radiotherapy treatment planning in patients with biochemical recurrence of prostate cancer (2008) (0)
- Clinical Introduction of freehand 3D SPECT to support Sentinel lymph node biopsy in Breast cancer. (2009) (0)
- EANM practice guideline for quantitative SPECT-CT (2022) (0)
- Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice (2022) (0)
- Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation. (2022) (0)
- MR imaging in patients with adenoid cystic carcinoma (2020) (0)
- TMIC-66. FIBROBLAST ACTIVATION PROTEIN: TISSUE EXPRESSION, POSITRON-EMISSION TOMOGRAPHY UPTAKE AND ITS PROGNOSTIC SIGNIFICANCE IN GLIOSARCOMAS AND GLIOBLASTOMAS (2022) (0)
- Lung Nodules Missed in Initial Staging of Breast Cancer Patients in PET/MRI—Clinically Relevant? (2022) (0)
- A Conversation Between Stefano Buono and Ken Herrmann (2019) (0)
- Intra-Individual Comparison of 124I-PET/CT and 124I-PET/MR Hybrid Imaging of Patients with Resected Differentiated Thyroid Carcinoma: Aspects of Attenuation Correction (2022) (0)
- Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system (2022) (0)
- Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT (2015) (0)
- Prediction of left lobe hypertrophy after right lobe radioembolization of the liver using a clinical data model with external validation (2022) (0)
- Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer (2023) (0)
- Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245. (2021) (0)
- The role of [11C]Choline PET/CT in patients with advanced prostate cancer (2007) (0)
- Chapter 2 – Lung Cancer (2018) (0)
- Comparison of the amino acid tracers FET and F-DOPA in glioblastoma patients (2013) (0)
- [18F]FLT-PET: Molecular imaging of proliferation is superior for very early predicton of response to targeted drug therapy in malignant lymphoma (2011) (0)
- FLT PET/CT-Guided Biopsy in the Evaluation of Cancer (2016) (0)
- Preclinical and Clinical Tumor Imaging with SPECT/CT and PET/CT (2011) (0)
- 317 CORRELATION OF HISTOPATHOLOGY AND RESULTS OF PRE-OPERATIVE [11C]CHOLINE PET/CT IN LYMPH NODE STAGING OF BLADDER CANCER PATIENTS SCHEDULED FOR RADICAL CYSTECTOMY (2011) (0)
- Positron emission tomography in pediatric and adult sarcoma (2015) (0)
- A-D. Patient with a primary NSCLC of the left upper lobe infiltrating the chest wall (A: ADC map from DW-MRI). (2015) (0)
- Additional value of PSMA-PET/CT in biochemical recurrence during follow-up of patients with prostate cancer. (2015) (0)
- Initial FDG uptake in patients with adenocarcinomas of the esophagogastric junction (AEG): Is it correlated to tumor localization and to patients' survival? (2007) (0)
- Performance of cone beam computed tomography in (2015) (0)
- NIMG-12. 18F-FLUORETHYLTYROSINE POSITRON EMISSION TOMOGRAPHY VERSUS MAGNETIC RESONANCE SPECTROSCOPY IN PREOPERATIVE DETECTION OF NEWLY DIAGNOSED GLIOMAS BY USING MACHINE LEARNING (2020) (0)
- Thymidine PET-CT (2010) (0)
- In-vivo proliferation imaging for early response assessment in patients with aggressive non-Hodgkins lymphoma (2011) (0)
- Subgroup analysis for the lung tumors only, showing a scatter plot of the voxel-by-voxel correlation of ADC and 18 F-FDG uptake. (2015) (0)
- Prediction of relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy (2014) (0)
- A Conversation Between Christoph Zindel and Ken Herrmann (2020) (0)
- LBA-25 RESIST-PC PHASE 2 TRIAL: 177LU-PSMA-617 RADIONUCLIDE THERAPY FOR METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (2019) (0)
- [Importance of FDG-PET/CT for surgery of rectal cancer]. (2014) (0)
- PD17-09 PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) SPARTAN-LIKE PATIENTS (PTS) NEGATIVE BY CONVENTIONAL IMAGING (2019) (0)
- 32nd International Austrian Winter Symposium (2016) (0)
- Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: A multicenter retrospective study. (2020) (0)
- FDG-PET avidity as a prognostic biomarker for overall survival in renal cell carcinoma. (2021) (0)
- Imaging of chemokine receptor 4 expression in neuroendocrine tumors in comparison to DOTATOC and FDG PET/CT (2016) (0)
- Nuclear Medicine Approaches to Treatment of Neuroendocrine Tumors (2015) (0)
- 68 Ga-PSMA-11 PET localizes residual prostate cancer after salvage node dissection (2020) (0)
- New technologies in radioguided surgery in complex anatomic areas (2016) (0)
- 68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a head-to-head comparison with DOTATOC and FDG PET/CT (2016) (0)
- C-11-choline PET/CT to monitor neoadjuvant androgen deprivation therapy and definitive radiotherapy in prostate cancer patients (2009) (0)
- Antifungal Therapy with Itraconazole Impairs Rituximab′s Anti-Lymphoma Effect by Inhibiting CD20 Recruitment to Lipid Rafts. (2009) (0)
- The value of FDG PET/CT in the assessment of patients with suspected recurrent melanoma: Correlation with S-100B, MIA and prognosis (2008) (0)
- Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study (2021) (0)
- Incidental detection of a tenosynovial giant cell tumour of the thigh on [68Ga]Ga-FAPI PET/CT: presentation of an unusual case. (2023) (0)
- MP60-15 USE OF INTRAOPERATIVE 68GALLIUM-PSMA CERENKOV LUMINESCENCE IMAGING FOR SURGICAL MARGINS IN RADICAL PROSTATECTOMY – A FEASIBILITY STUDY (2019) (0)
- Prognostic Value of Metabolic Tumor Volume after Induction Chemotherapy in Stage IIIA/B Non-Small-Cell Lung Cancer – Secondary Analysis of a Randomized Phase 3 Trial (2019) (0)
- Therapy Monitoring with Fluorine-18 FDG-PET and Fluorine-18 FDG-PET/CT. (2008) (0)
- Freehand SPECT: First in-vivo evaluation and comparison to conventional lymphatic mapping (2009) (0)
- PET/CT for restaging breast cancer - Impact on patient management and patient outcome (2008) (0)
- Cost-effectiveness of anatometabolic imaging with PET/CT for staging of NSCLC (2009) (0)
- C O N T I N U I N G E D U C a T I O N Spect/ct* (2008) (0)
- Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors (2017) (0)
- Uptake quantification of sentinel lymph nodes in breast cancer using SPECT/CT (2009) (0)
- Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. (2020) (0)
- [Structured reporting in oncologic hybrid imaging: a consensus recommendation]. (2020) (0)
- Abstract 4049: Early prediction of response to targeted drugs treatment in malignant lymphoma and sarcoma using in vivo proliferation marker 18F-FLT (2012) (0)
- NIMG-32. COMPARISON OF L-METHYL-11C-METHIONINE POSITRON EMISSION TOMOGRAPHY WITH MAGNETIC RESONANCE SPECTROSCOPY IN DETECTING NEWLY DIAGNOSED GLIOMA (2018) (0)
- Freehand SPECT for sentinel lymph node biopsy: First clinical experience (2010) (0)
- [Structured reporting in oncologic hybrid imaging: a consensus recommendation]. (2020) (0)
- Post-radiosynovectomy imaging utilizing Erbium-169 citrate. (2019) (0)
- Influence of a newly introduced serotonin-specific antidepressant on cardiac MIBG uptake (2015) (0)
- Assessing Functional Androgen Receptor Pathway Activity in Response to Radiotherapy Using hK2-targeted PET Imaging (2022) (0)
- CXCR4-Directed Endoradiotherapy as New Treatment Option in Advanced Multiple Myeloma (2018) (0)
- Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapy. (2021) (0)
- Relationship between the degree of water diffusivity and glucose metabolism, and their potential biological correlate. (2015) (0)
- Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX). (2018) (0)
- Influence of transmission-based attenuation correction on presynaptic dopamine transporter SPECT (2014) (0)
- Abstract 5302: Early prediction of response to therapy in malignant lymphoma using non-invasive [18F]FLT-PET imaging from animal to human model (2011) (0)
- Molecular imaging of individual tumor metabolism and early prediction of response to therapy with sorafenib in malignant sarcoma (2012) (0)
- Reply by Authors. (2019) (0)
- A-C. The tumors were divided into voxel rings starting from the periphery to the tumor center (A). (2015) (0)
- Activation of brown adipose tissue as a response to hypothyroidism (2015) (0)
- Changes in the tumor glucose-uptake measured by 18F-FDG PET with two weeks of single-agent cetuximab in localized squamous cell carcinoma of the esophagus. (2013) (0)
- 18f-FDG-PET imaging as an early survival predictor in patients with high-grade soft tissue sarcomas undergoing neoadjuvant therapy. (2012) (0)
- 124 TUMOR CONFIGURATION OF PROSTATE CANCER (PCA) INFLUENCES THE SENSITIVITY OF [11C]CHOLINE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/CT) (2011) (0)
- Endocrine Abstracts vol 56 (2016) (0)
- Evaluation of 3-deoxy-3-18fluorothymidine PET (FLT-PET) for the detection of pancreatic cancer - Comparison to FDG-PET/CT (2009) (0)
- Predictive value of initial 18FLT-uptake in patients with diffuse large B cell lymphoma (DLBCL) undergoing R-CHOP treatment (2010) (0)
- [18F]FLT Is Superior to [18F]FDG to Early Predict Response to Specific Inhibitors of NPM-ALK-Dependent Pathways In a Human ALCL Xenograft Model (2010) (0)
- Intraperitoneal contrast-enhanced small animal FDG PET/CT for improved abdominal delineation and uptake quantification (2021) (0)
- Reducing emission time in prostate cancer patients undergoing Ga-68-PSMA PET/CTon a digital system (2020) (0)
- MP20-16 68GA-PSMA-11 PET/CT VS 18F-FLUCICLOVINE PET/CT: A CASE SERIES IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL RECURRENCE (2018) (0)
- Metastasiertes (2020) (0)
- 1606P Developing a readiness assessment framework for radioligand therapy (2020) (0)
- Hybridbildgebung (2020) (0)
- Esophageal cancer: diagnostic work-up and response assessment: The role of positron emission tomography (2010) (0)
- [Oncological theranostics in nuclear medicine]. (2022) (0)
- Real-World Data as an Evidence Source in Nuclear Medicine (2020) (0)
- 1925 TUMOR CONFIGURATION OF PROSTATE CANCER (PCA) INFLUENCES THE SENSITIVITY OF [11C]CHOLINE POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY (PET/CT) (2011) (0)
- Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy. (2023) (0)
- Letter from the Guest Editors. (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ken Herrmann?
Ken Herrmann is affiliated with the following schools:
